Purpose of review Zika virus (ZIKV) has only recently been exposed as a significant public health threat, and much of our limited knowledge of its pathogenesis and triggered immune responses were discovered in only the last few years. There are currently no ZIKV-specific therapeutics or vaccines available. This review seeks to bring the reader up-to-date with the latest developments in finding a way to combat this emerging infectious disease.
INTRODUCTION
Although Zika virus (ZIKV) was first discovered in 1947, it garnered little attention until this last decade because of an association with only mild symptoms and less than 20 reported human cases [1 & ] . However, at some point during its migration from Africa to Asia and subsequently the Pacific Islands, the virus mutated [2 & ,3 & ,4], changing the manifestations of its infection. Not only has it become more pathogenic, causing Guillain-Barré syndrome (GBS) and congenital malformations, but it has acquired (or perhaps we are simply just now uncovering) alternate routes of transmission not seen in any other mosquito-borne virus [1 & ,5 && ]. These concerning developments have stirred public frenzy towards finding a means of halting the spread of this pandemic, as well as treatments to preserve the health of unborn children at risk of neurologic devastation [6 & ]. This review will highlight the key advancements made over the last 18 months in creating a ZIKV vaccine and in finding therapeutic options that neutralize or suppress virus replication and therefore counter its damaging effects.
THE FOUNDATIONS FOR BUILDING A ZIKV VACCINE
Fear over the potential global transmission of ZIKV is reminiscent of the public response to the Ebola virus (EBOV) outbreak in West Africa in 2014. However, unlike the high levels of morbidity and mortality associated with hemorrhagic fever viruses such as EBOV, ZIKV infection is symptomatic in only 20% of noncongenital cases, few of which even require hospitalization [1 years of former research by the U.S. defense department, enabling the rapid development and production of a vaccine within a year of the outbreak ] that research in this field exploded. President Obama called for increased funding towards ZIKV research, particularly vaccine development, some of which was necessarily re-appropriated from money originally intended to combat EBOV [8] .
Although we are faced with the challenge of creating a vaccine for a virus whose pathogenesis and host immune response we are only beginning to understand, we have the benefit of previous advancements made towards the study of related flaviviruses [9 & ]. Members of this genus have linear, positive-sense nonsegmented RNA genomes inside enveloped capsids. The viruses are predominantly transmitted by either ticks or mosquitoes, with a propensity to cause either neurologic or hemorrhagic disease. As the route of transmission is by insect bite to the skin with initial propagation in local keratinocytes, fibroblasts, and immature dendritic cells [10 && ], many flavivirus vaccines are administered subcutaneously to target those same cells. The first discovered and approved for human use is the 17D strain of yellow fever virus, which accumulated multiple stable and attenuating mutations throughout its genome after serial passaging in vitro. 13 ]. These recombinant vaccines replace the genes encoding the envelope (E) and premembrane (prM) proteins of 17D with the ones from their respective viruses (the DENV vaccine includes genes for the four most common serotypes) [14 & ]. E is the surface antigen thought to be the predominant target of neutralizing antibody responses to flaviviruses. Other recombinant live DENV vaccines still in clinical trials include one that instead uses an attenuated DENV2 serotype virus as the backbone for the other three serotypes [15] , and one comprised of four attenuated DENV strains [16] . An advantage of live attenuated vaccines is that they can induce long-lasting protective immune responses, similar to infection with the original virus. Such a strategy could be used for a ZIKV vaccine, although it is not yet known whether ZIKV infection results in life-long immunity, nor whether distinct serotypes will emerge [3 & ]. Unfortunately, live vaccines also require more rigorous safety testing, as they can be dangerous to immunocompromised hosts, such as pregnant women and their fetuses (ironically, the population we are most interested in protecting from ZIKV). Despite the promising results of the current DENV vaccine [14 & ], it still took over two decades of testing to win approval for human use [14 & ,16,17] . Other approaches to flavivirus immunization have also been tested in humans, such as intramuscular injection with purified formalin-inactivated tick-borne encephalitis virus, JEV or DENV, or with recombinant subunits of the DENV E and nonstructural protein 1 (NS1) proteins [11 & ,17-19] . The NS1 of flaviviruses contains highly conserved areas within a secreted hexamer form that is involved in immune evasion, and has been targeted in other vaccines [20 & ]. Although less immunogenic than live viruses, inactivated and subunit vaccines can be tailored to deliver precise amounts of antigen, without the risk of live viruses in a multisubtype formulation interfering with one another (a potential explanation for why the DENV tetravalent attenuated vaccine is not as effective against certain serotypes) [19] . Simultaneous immunization against all serotypes is important in preventing hemorrhagic complications that can arise in natural DENV infection when memory immune responses to one serotype later aggravate the disease caused by a different serotype [18] . Although this
KEY POINTS
ZIKV is an emerging global public health threat, with no treatments or vaccines currently available.
Our understanding of ZIKV is founded on limited research from only the last few years, therefore medical intervention strategies currently draw on knowledge of related flavivirus infections.
The developing fetus is most at risk of ZIKV complications, therefore pregnant women are an especially important target for treatments and vaccines; however, this presents challenges for ensuring both efficacy and safety in this immunocompromised population.
Gaps in our ZIKV knowledge base, animal model limitations, and concern for adverse immune responses and teratogenic effects, all pose challenges to drug developers, and could prolong the wait before a ZIKV vaccine or treatment becomes available.
phenomenon is not well understood, antibodydependent enhancement (ADE) of disease is a potential mechanism [19] . As ZIKV and DENV are closely related, there is a possibility that ZIKV infection in a population previously exposed to DENV 
CURRENTLY RECOMMENDED MEDICAL INTERVENTIONS
Similar to other flavivirus infections, there are currently no virus-specific therapeutic interventions against ZIKV. After a 3-14-day incubation period, the infection remains asymptomatic in 80% of patients, while the remainder have an array of symptoms that can include low grade fever, maculopapular rash, myalgia, arthralgia, and conjunctivitis Zika vaccine and therapeutics Quanquin et al. (Table 2 ). In addition, 3-methyladenine (3-MA), an inhibitor of autophagosome formation, was shown in vitro to reduce ZIKV copy numbers in infected fibroblasts [10 && ]. EGCG, a polyphenol found in green tea that has broad antiviral properties, was also found to inhibit ZIKV entry into cultured cells [40] . Although these studies are preliminary, they demonstrate that progress is being made towards a cure, which could potentially be attainable long before a ZIKV vaccine.
Passive ]. Although mouse models of ZIKV-induced microcephaly exist for which these drugs could be tested, screening for safety and effectiveness in pregnant women will likely take years. The target populations will most likely be women of childbearing age and their partners who are at risk in endemic areas or who plan to travel to endemic areas.
CONCLUSION
We must rely on lessons learned from related flaviviruses to quickly design new therapeutic and prophylactic ZIKV interventions. Three vaccines have already shown promise in monkeys, and many more are in development. ZIKV antivirals are still in early testing, although mAbs have worked for other infections and could be easier to screen and produce. Each endeavor has the added challenge of proving safety in pregnant women, and accounting for possible ZIKV induction of adverse antibody responses leading to GBS and potentially ADE in populations with pre-existing flavivirus immunity. Therefore, immunizations and treatments against ZIKV will require prolonged testing. 
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